Literature DB >> 31979229

Reply to Comment on "Malfitano, A.M. et al. Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer" Cancers 2019, 11, 1532.

Anna Maria Malfitano1, Sarah Di Somma1, Nella Prevete1, Giuseppe Portella1.   

Abstract

Our work is focused on the future clinical use of oncolytic viruses (OVs) for the treatment of aggressive thyroid carcinomas. Therefore, we provide a brief description of the overall use of OVs in the clinic. Rigvir is among the few OVs that have already been used for the treatment of patients, and studies describing its effects have been briefly commented and cited in our text [1]. [...].

Entities:  

Year:  2020        PMID: 31979229      PMCID: PMC7073196          DOI: 10.3390/cancers12020281

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


Our work is focused on the future clinical use of oncolytic viruses (OVs) for the treatment of aggressive thyroid carcinomas. Therefore, we provide a brief description of the overall use of OVs in the clinic. Rigvir is among the few OVs that have already been used for the treatment of patients, and studies describing its effects have been briefly commented and cited in our text [1]. The comment of Dr. Alberts aims to clarify the actual state of the oncolytic ECHO-7 virus Rigvir and its approval as a therapeutic opportunity. The comment properly declares that Rigvir has been approved in former Soviet Union countries such as Latvia in 2004, Georgia in 2015, Armenia in 2016, and Uzbekistan in 2018 [2]. In the sentence stated in our publication: “This virus has not met the required standard regulation for European or U.S. approval, further studies are in progress to better evaluate its therapeutic potential”, we did not doubt the efficacy of Rigvir. Indeed, many pre-clinical and clinical studies have been performed. However, it is clear that Rigvir use needs to be supported by further and updated preclinical and clinical studies as also argued in the paper “The advent of oncolytic virotherapy in oncology: The Rigvir® story” by Dr. Alberts, where “the results will be confirmed and updated by modern clinical studies”. In our work, it is not stated that the use of Rigvir was rejected by European or U.S. agencies, but likely that more detailed studies are required to propose Rigvir for their approval. Overall, if the readers require more specific information regarding Rigvir, proper references have been included by us and we are sure that more focused reviews such as those of Dr. Alberts, might clarify any “unclear” sentences.
  2 in total

Review 1.  The advent of oncolytic virotherapy in oncology: The Rigvir® story.

Authors:  Pēteris Alberts; Andra Tilgase; Agnija Rasa; Katrīna Bandere; Dite Venskus
Journal:  Eur J Pharmacol       Date:  2018-09-01       Impact factor: 4.432

Review 2.  Virotherapy as a Potential Therapeutic Approach for the Treatment of Aggressive Thyroid Cancer.

Authors:  Anna Maria Malfitano; Sarah Di Somma; Nella Prevete; Giuseppe Portella
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  2 in total
  1 in total

1.  PD-1 blockade delays tumor growth by inhibiting an intrinsic SHP2/Ras/MAPK signalling in thyroid cancer cells.

Authors:  Federica Liotti; Narender Kumar; Nella Prevete; Maria Marotta; Daniela Sorriento; Caterina Ieranò; Andrea Ronchi; Federica Zito Marino; Sonia Moretti; Renato Colella; Efiso Puxeddu; Simona Paladino; Yoshihito Kano; Michael Ohh; Stefania Scala; Rosa Marina Melillo
Journal:  J Exp Clin Cancer Res       Date:  2021-01-07
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.